The treatment of glioblastoma by Gregorian can prolong survival

Glioblastoma (GBM) has hereditary heterogeneity and poor prognosis in patients.
recent REGOMA trial results show that regorafeib extends the overall lifetime (OS) of patients with relapsed GBM.
Alessandra Santangelo of the Department of Biomedical and Sports Neuroscience at the University of Verona, Italy, analyzed tumor specimens from patients in the REGOMA trial with a view to identifying the molecular characteristics of tumors that are effective in the treatment of rigoffinib.
results were published online in July 2020 in Neuro-Oncol.
The researchers collected 72 paraffin specimen slices from the first surgery in 119 GBM patients in the REGOMA trial, 36 of which were in the Rigoffini group and 36 in the Lomostin group.
extract mRNA and miRNA from paraffin specimens.
set up high expression groups and low expression groups based on the medium expression level value, and calculate two groups of OS and progress-free lifetime (PFS) respectively.
The first part of the alternative mRNA and miRNA was obtained from p≤01 specimens of PFS and OS, and the second part of the more stringent mRNA and miRNA was obtained from the extended samples of the Rigoffini group OS.
mRNA analysis found that high expression HIF1A, CTSK, SLC2A1, KLHL12, CDKN1A, CA12, WDR1, CD53 mRNA and low expression C were higher in the Rigoffini group than in the Lomostin group Patients with BR4, NIFK-AS1, RAB30-DT mRNA had significantly longer OS, with the medium OS in 10.6-20.8 months (Rigoffinist) and 5.4-8.4 months (Lomostin group) respectively.
PFS between the two groups, but the difference is slightly smaller.
further analysis found that in the Rigoffini group, the lifetimes of patients with high expression HIF1A and CDKN1AmRNA were significantly extended (p=0.0011 and 0.00083).
of high expression patients with HIF1A and CDKN1A had a medium survival of 20.8 months, while the low expression group had 5.9 months and June, respectively.
miRNA analysis found 10 miRNAs with expression differences between the Lomostin and Rigoffini groups.
in patients with OS extension in the Rigofini group, low expression miR-93-5p, miR-203a-3p, miR-17-5p, let-7c-3p, miR-101-3p, miR-3607-3p, miR-6516-3p, miR-301a-3p and miR-23b-3p and high expression miR-222-3p.
OS was 10.6-13.4 months (Rigoffini group) and 5.5-7.3 months (Lomostin group) respectively (Figure 1).
there are differences between the two groups of PFS, but the range of differences is slightly smaller.
further analysis found that in the Rigofini treatment group, patients with low expression miR-93-5p, miR-3607-3p and miR-301a-3p had significantly longer OS (p=0.040, 0.018 and 0.013).
the low expression group OS was 12.2-14.6 months compared to the high expression group of 3 miRNAs (OS 7.1-7.6 months).
1. Differences in the survival of miRNAs at different expression levels between the Rigoffini and Lomostin groups.
conclusion, the author points out that on the basis of the REGOMA trial, it is found that rigoffinib is effective in prolonging the life of relapsed GBM and provides a certain basis for future clinical drug selection.